Hookipa Pharma Inc (NASDAQ:HOOK – Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 24,200 shares, a decrease of 9.7% from the August 15th total of 26,800 shares. Based on an average daily trading volume, of 39,500 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.3% of the company’s shares are sold short.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on HOOK shares. HC Wainwright boosted their price objective on Hookipa Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, June 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $50.00 price target on shares of Hookipa Pharma in a research note on Tuesday, May 21st. Finally, JMP Securities boosted their price objective on shares of Hookipa Pharma from $23.00 to $24.00 and gave the company a “market outperform” rating in a research report on Friday, August 9th.
View Our Latest Report on Hookipa Pharma
Institutional Investors Weigh In On Hookipa Pharma
Hookipa Pharma Stock Performance
NASDAQ HOOK traded down $0.16 on Wednesday, reaching $4.62. 51,136 shares of the stock traded hands, compared to its average volume of 60,927. Hookipa Pharma has a 12 month low of $4.10 and a 12 month high of $11.30. The company has a market cap of $45.71 million, a price-to-earnings ratio of -0.94 and a beta of 0.84. The company has a fifty day moving average price of $5.39 and a 200-day moving average price of $6.84.
Hookipa Pharma (NASDAQ:HOOK – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.44) by ($0.08). Hookipa Pharma had a negative net margin of 93.16% and a negative return on equity of 36.81%. The firm had revenue of $1.29 million during the quarter, compared to the consensus estimate of $5.68 million. As a group, research analysts anticipate that Hookipa Pharma will post -2.56 earnings per share for the current fiscal year.
Hookipa Pharma Company Profile
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Read More
- Five stocks we like better than Hookipa Pharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- How Much Can You Make in Stocks in One Month?
- Roth IRA Calculator: Calculate Your Potential Returns
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.